Repatha vs Praluent: Head-to-Head Efficacy for Women

What Are Repatha and Praluent, and How Do They Work?

Both drugs belong to the same class: monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9), the enzyme that degrades LDL receptors on liver cells. By blocking PCSK9, these drugs allow more LDL receptors to remain on the liver surface, pulling more LDL out of the bloodstream. The mechanism is identical between the two agents. What differs is the specific antibody molecule, the dosing schedule, the approved indications, and, in some cases, the cost and access.

Why This Matters for Women Specifically

Cardiovascular disease is the leading cause of death in women in the United States, responsible for one in five female deaths. Women's cardiovascular risk trajectories differ from men's in a clinically meaningful way: estrogen suppresses PCSK9 expression during the reproductive years, meaning LDL levels are often lower before menopause. After menopause, PCSK9 activity rises alongside LDL, which is one reason LDL cholesterol increases by an average of 10 to 14 mg/dL in the years surrounding the final menstrual period. This perimenopausal lipid shift is underappreciated and often undertreated.

Women with PCOS, type 2 diabetes, familial hypercholesterolemia, or a history of preeclampsia carry elevated lifetime cardiovascular risk independent of age. These groups may need PCSK9 inhibitors earlier than the general female population.

The Basic Pharmacology

Evolocumab (Repatha, Amgen) is a fully human IgG2 monoclonal antibody. Alirocumab (Praluent, Sanofi/Regeneron) is a fully human IgG1 monoclonal antibody. Both are administered by subcutaneous injection via prefilled auto-injector pen. Bioavailability after subcutaneous injection is approximately 72 percent for evolocumab and roughly similar for alirocumab, though the IgG subclass differences produce slightly different half-lives: evolocumab has a half-life of approximately 11 to 17 days, and alirocumab approximately 17 to 20 days. Neither is metabolized by cytochrome P450 enzymes, so drug-drug interactions through that pathway are not a concern.

FOURIER vs ODYSSEY OUTCOMES: What the Big Trials Actually Found

No randomized head-to-head trial has directly compared evolocumab to alirocumab. Any comparison between the two drugs relies on cross-trial analysis, which carries real limitations: different patient populations, different statin backgrounds, different LDL entry criteria. Keep that caveat firmly in mind.

FOURIER: The Evolocumab Trial

FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) enrolled 27,564 patients with established atherosclerotic cardiovascular disease (ASCVD) who were already on optimized statin therapy. Evolocumab reduced LDL from a median of 92 mg/dL to 30 mg/dL, a 59 percent reduction. The primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) fell by 15 percent relative risk reduction, with a hazard ratio of 0.85 (95% CI 0.79 to 0.92).

Women made up 27 percent of the FOURIER population, approximately 7,400 participants. The sex-specific subgroup showed a directionally consistent benefit, though the confidence intervals were wider given the smaller sample. This is the evidence-gap problem: women were enrolled at rates that don't reflect the female cardiovascular disease burden.

ODYSSEY OUTCOMES: The Alirocumab Trial

ODYSSEY OUTCOMES enrolled 18,924 patients who had experienced acute coronary syndrome (ACS) within the prior one to 12 months and were on high-intensity or maximally tolerated statin therapy. The entry LDL criterion was at least 70 mg/dL (or non-HDL at least 100 mg/dL, or apolipoprotein B at least 80 mg/dL). Alirocumab reduced LDL from a mean of 87 mg/dL to 40 mg/dL, a 54 percent reduction. The primary endpoint (coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) fell by 15 percent relative risk reduction, with a hazard ratio of 0.85 (95% CI 0.78 to 0.93).

Women comprised approximately 25 percent of the ODYSSEY OUTCOMES population. Again, sex-specific subgroup analysis showed directional consistency but wider confidence intervals.

Cross-Trial Comparison Table

| Feature | Evolocumab (FOURIER) | Alirocumab (ODYSSEY OUTCOMES) | |---|---|---| | Trial population | Established ASCVD on statin | Post-ACS on high-intensity statin | | Baseline LDL (median/mean) | 92 mg/dL | 87 mg/dL | | LDL achieved | 30 mg/dL | 40 mg/dL | | Relative MACE reduction | 15% (HR 0.85) | 15% (HR 0.85) | | Median follow-up | 2.2 years | 2.8 years | | Women enrolled | ~27% | ~25% | | Absolute risk reduction | ~1.5% | ~1.6% |

The strikingly similar efficacy numbers are real, but they don't confirm equivalence. FOURIER enrolled a broader stable ASCVD group; ODYSSEY OUTCOMES focused on a higher-acuity post-ACS population with slightly longer follow-up.

Dosing Schedules and What That Means Day-to-Day

Evolocumab (Repatha)

Evolocumab comes in two dosing options approved by the FDA:

• 140 mg subcutaneously every two weeks
• 420 mg subcutaneously once monthly (three 140 mg injections given consecutively within 30 minutes, or via a single-use on-body infusor)

The monthly option can improve adherence for women who prefer fewer injection days. The on-body infusor takes about nine minutes to deliver the 420 mg dose and may suit women who find self-injection daunting.

Alirocumab (Praluent)

Alirocumab is FDA-approved at:

• 75 mg subcutaneously every two weeks (starting dose for most patients)
• 150 mg subcutaneously every two weeks (if LDL response is insufficient at 75 mg)

Alirocumab's titratable dosing is useful when you want to start conservatively, particularly if baseline LDL is modestly elevated or if you're concerned about driving LDL very low. The 75 mg starting dose gives a LDL reduction of roughly 40 to 50 percent; stepping up to 150 mg achieves closer to 60 percent reduction. This flexibility does not exist with evolocumab.

Women-Specific Efficacy and Risk Data

Interpreting cardiovascular trial data through a women's-health lens requires a structured framework, because the aggregate trial results consistently underrepresent female participants. Here is how to apply the available evidence to a woman's clinical situation across life stages.

Reproductive Years (Ages 18 to 45)

Women in their reproductive years rarely need PCSK9 inhibitors unless they carry a diagnosis of familial hypercholesterolemia (FH), have established ASCVD from another cause (such as prior MI, peripheral arterial disease, or a high-risk autoimmune condition like lupus), or have PCOS with severe dyslipidemia refractory to statins and lifestyle modification. Familial hypercholesterolemia affects approximately 1 in 250 people, and women with heterozygous FH who are not pregnant or breastfeeding are appropriate PCSK9 candidates when statins are insufficient.

Hormonal contraception (particularly combined oral contraceptives containing ethinyl estradiol) can modestly raise triglycerides and lower LDL. This does not contraindicate PCSK9 therapy but should be factored into the overall lipid management picture.

Perimenopause (Typically Ages 45 to 55)

This is arguably the most clinically underserved life stage for cardiovascular risk. During perimenopause, fluctuating and then declining estrogen leads to measurable changes in lipid metabolism: LDL rises, HDL may fall modestly, and small dense LDL particles (the more atherogenic fraction) increase. One prospective study found LDL increased by 9 mg/dL on average across the menopausal transition, with higher increases in women who had greater estrogen decline.

If a perimenopausal woman is already on a statin and her LDL remains above guideline targets, this is the moment to reconsider escalation, including PCSK9 inhibitors. Neither FOURIER nor ODYSSEY OUTCOMES specifically reported outcomes by menopausal status, which is a genuine evidence gap.

Postmenopause

The majority of women who will need PCSK9 inhibitors fall into this group, particularly those with established ASCVD, type 2 diabetes, or FH. Postmenopausal women on menopausal hormone therapy (MHT) may have a modified lipid profile: oral estrogen tends to lower LDL but raise triglycerides, while transdermal estrogen has a more neutral triglyceride effect. PCSK9 inhibitors work independently of hormone therapy status, and no pharmacokinetic interaction has been described between MHT and either PCSK9 agent.

Pregnancy, Lactation, and Contraception

Both evolocumab and alirocumab are FDA Pregnancy Category not formally assigned under the newer labeling system, but animal data and mechanism raise concern. Here is what the data show:

Pregnancy: Animal reproduction studies for evolocumab showed no adverse developmental outcomes at doses up to 12 times the human exposure level. However, PCSK9 plays a role in fetal lipid metabolism, and cholesterol is critical for normal fetal development. Human data in pregnancy are extremely limited. The prescribing information for both drugs states that use during pregnancy is not recommended and should be avoided unless the benefit clearly outweighs the risk. Given that cardiovascular events requiring PCSK9 therapy are rare during pregnancy, and safer alternatives (such as bile acid sequestrants, which are not systemically absorbed) exist for pregnant women with FH, the practical guidance is: stop both drugs before attempting conception or immediately upon confirmed pregnancy.

Lactation: IgG monoclonal antibodies are present in human breast milk in small amounts. Whether evolocumab or alirocumab transfers to breast milk in clinically meaningful concentrations is unknown. Given the lack of data and the availability of alternative therapies for the postpartum period, both manufacturers advise against use during breastfeeding. A woman who needs aggressive LDL lowering postpartum and is not breastfeeding may resume PCSK9 therapy after delivery.

Contraception requirement: Women of reproductive potential who are prescribed either drug should use effective contraception during treatment. This is not a formal black-box requirement (as it is for teratogens like isotretinoin), but it is the clinically responsible recommendation given the unknown fetal risk and the half-life of these antibodies (11 to 20 days), meaning the drug remains in the body for weeks after the last injection.

A note for women with PCOS: PCOS is associated with higher baseline LDL and cardiovascular risk. If you have PCOS, are using a PCSK9 inhibitor, and are also pursuing fertility treatment, discuss timing of drug discontinuation with your care team well before your planned conception cycle.

Is One Drug Better Than the Other for Women?

No trial has randomized women to evolocumab vs alirocumab to answer this directly. Based on available cross-trial data and pharmacological properties, the answer is that neither drug is definitively superior in efficacy for women as a group. The 15 percent MACE reduction seen in both trials, the similar magnitude of LDL lowering, and the identical mechanism make these drugs functionally equivalent at the population level.

Where meaningful differences do exist:

Dosing Flexibility

Alirocumab's titratable dosing (75 mg stepping to 150 mg every two weeks) gives clinicians more control. If a woman's baseline LDL is only modestly above target, starting at 75 mg and reassessing avoids over-treating. Evolocumab does not offer this step-up option.

Indicated Populations

Evolocumab holds an FDA indication for reducing MACE in established ASCVD (the FOURIER population) and also for LDL lowering in primary hyperlipidemia and FH. Alirocumab holds an FDA indication for reducing MACE after ACS (the ODYSSEY OUTCOMES population) and for LDL lowering in primary hyperlipidemia and FH. In a woman with a recent ACS, alirocumab's trial data are arguably a closer match. In a woman with stable established ASCVD, evolocumab's data are a closer match. In practice, clinicians use either drug across both populations.

Cost and Access

Both drugs have list prices in the range of $5,500 to $6,000 per year in the United States, but patient assistance programs and formulary-specific pricing can make one dramatically cheaper than the other for a given patient. This is often the deciding factor in clinical practice.

Who Is a Candidate for PCSK9 Therapy? A Life-Stage Guide for Women

Women Who Should Have a PCSK9 Conversation Now

• Postmenopausal women with established ASCVD whose LDL remains above 70 mg/dL on maximally tolerated statin therapy
• Women of any age with heterozygous or homozygous familial hypercholesterolemia
• Women post-ACS whose LDL remains above 70 mg/dL on high-intensity statin
• Women with statin intolerance (documented myopathy or intolerable side effects at any dose) whose LDL is significantly elevated
• Perimenopausal women with ASCVD whose LDL has risen above guideline targets despite statin optimization

Women for Whom PCSK9 Therapy Is Premature or Inappropriate

• Women who are pregnant or actively breastfeeding (see section above)
• Women without established ASCVD or FH whose LDL is modestly elevated and who have not first tried statin therapy and lifestyle changes
• Women who are trying to conceive without first discussing a drug-free interval with their cardiologist and OB-GYN

The 2022 ACC/AHA guideline on cardiovascular risk management recommends PCSK9 inhibitors as an adjunct to maximally tolerated statin therapy in very-high-risk patients whose LDL remains at or above 70 mg/dL. "Very high risk" includes prior ACS, stroke, peripheral arterial disease, or multiple major risk factors. Women with a history of preeclampsia, which is now recognized as a cardiovascular risk-equivalent, may warrant earlier intensification of lipid therapy, though specific PCSK9 data in this group are absent.

Side Effects: What to Watch for as a Woman

Both drugs have favorable safety profiles in trial data. The most common adverse effects are injection-site reactions (bruising, redness, pain at the injection site), occurring in approximately 3 to 5 percent of patients. Neither drug has shown a meaningful signal for muscle toxicity, which is the side effect women most associate with statins.

Neurocognitive effects were a post-market concern raised after early case reports. The EBBINGHAUS trial, a pre-specified cognitive substudy of FOURIER with 1,974 participants, found no difference in cognitive function between evolocumab and placebo over 19 months of follow-up. A comparable analysis of alirocumab from ODYSSEY OUTCOMES did not show a cognitive signal either.

One consideration specific to women: very low LDL levels (below 20 to 25 mg/dL) can theoretically affect steroid hormone synthesis, since cholesterol is the precursor for estrogen, progesterone, and testosterone. Neither FOURIER nor ODYSSEY OUTCOMES showed hormonal disruption as a reported outcome. This area warrants further study in women, particularly those approaching menopause whose ovarian hormone production is already declining. The evidence gap here is real, and it is honest to name it.

Switching From One PCSK9 Inhibitor to the Other

Switching from Repatha to Praluent, or vice versa, is clinically straightforward in pharmacological terms. Both agents work through the same mechanism, and no washout period is needed between them. In practice, the most common reason to switch is insurance formulary change, with one drug suddenly becoming preferred or the other losing coverage. A second reason is injection-site tolerability; some women find the auto-injector for one drug more comfortable than the other. A third is dosing convenience, with some women preferring the monthly 420 mg evolocumab option over a biweekly injection schedule.

When switching, your clinician will typically recheck a fasting lipid panel four to eight weeks after the switch to confirm LDL response is maintained. There is no evidence that prior exposure to one PCSK9 inhibitor blunts the response to the other.

The Evidence Gap: What We Still Don't Know About Women

Women were enrolled at 25 to 27 percent rates in both major PCSK9 trials, yet women account for nearly half of cardiovascular deaths. This enrollment gap means:

• Sex-specific subgroup analyses are underpowered to detect meaningful differences in efficacy or harm
• Menopausal status, hormone therapy use, and reproductive history were not systematically analyzed as effect modifiers in either trial
• No trial has specifically enrolled women with PCOS, postpartum cardiomyopathy, or a history of preeclampsia as the primary population

The American Heart Association's 2020 call for sex-specific cardiovascular research specifically named PCSK9 inhibitors as an area where women-specific data are needed. Until those trials exist, clinicians apply FOURIER and ODYSSEY OUTCOMES data to female patients with the acknowledgment that we are extrapolating from a population that was predominantly male.

As a WomanRx clinician guideline: "The benefit-to-risk ratio for PCSK9 inhibitors in women with established ASCVD or familial hypercholesterolemia is strongly positive based on available data, despite the enrollment gap. The extrapolation is reasonable because the biological mechanism of PCSK9 inhibition does not differ by sex. The gap matters most for nuanced questions about dose optimization and long-term hormonal effects, which remain unanswered."

Practical Next Steps

If your LDL remains above 70 mg/dL on a maximally tolerated statin and you have established ASCVD or familial hypercholesterolemia, ask your clinician to assess whether a PCSK9 inhibitor is appropriate. Bring a copy of your most recent fasting lipid panel. Ask specifically about your insurance formulary, because cost, not efficacy, is the primary differentiator between these two drugs for most women.

If you are perimenopausal and your LDL has risen in the last two to three years, request a full cardiovascular risk assessment using the ACC/AHA pooled cohort equations and discuss whether statin escalation should precede PCSK9 consideration.

Women with PCOS, a history of preeclampsia, or type 2 diabetes who have not yet had a formal cardiovascular risk stratification should request one. These conditions raise lifetime risk in ways that standard risk calculators may underestimate.